Serum oestrogen receptor α and Β bioactivity are independently associated with breast cancer: a proof of principle study

British Journal of Cancer

Volumn 101, Issue 1, 2009, Pages 160-165

  Widschwendter, M ^a   Lichtenberg Frate, H ^b   Hasenbrink, G ^b   Schwarzer, S ^b   Dawnay, A ^c   Lam, A ^c   Menon, U ^a   Apostolidou, S ^a   Raum, E ^d   Stegmaier, C ^e   Jacobs, I J ^a   Brenner, H ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e Saarland Cancer Registry   (Germany)

Author keywords

Breast cancer; Oestrogen receptor; Risk; Serum bioactivity

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GREEN FLUORESCENT PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DRUG ACTIVITY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN RESPONSIVE ELEMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK; SACCHAROMYCES CEREVISIAE; TRANSACTIVATION; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; DNA RESPONSIVE ELEMENT; GENETICS; MIDDLE AGED; PREDICTION AND FORECASTING; RISK FACTOR; TRANSCRIPTION INITIATION;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RESPONSE ELEMENTS; RISK FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 67649876267     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605106     Document Type: Article

References (26)

1. Aronica SM, Katzenellenbogen BS (1993) Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7: 743 - 752
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139
3. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 130: 270-277
4. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300
5. Cvoro A, Paruthiyil S, Jones JO, Tzagarakis-Foster C, Clegg NJ, Tatomer D, Medina RT, Tagliaferri M, Schaufele F, Scanlan TS, Diamond MI, Cohen I, Leitman DC (2007) Selective activation of estrogen receptor- beta transcriptional pathways by an herbal extract. Endocrinology 148: 538-547
6. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71 - 85
7. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C (2007) Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67: 2062-2071
8. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292-1299
9. Hasenbrink G, Sievernich A, Wildt L, Ludwig J, Lichtenberg-Frate H (2006) Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J 20: 1552 - 1554
10. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905 - 931
11. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA (1993) Peptide growth factors elicit estrogen receptor- dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7: 992-998
12. Key T, Appleby P, Barnes I, Reeves G, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616
13. Klein KO, Baron J, Barnes KM, Pescovitz OH, Cutler Jr GB (1998) Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone- releasing hormone agonist. J Clin Endocrinol Metab 83: 2387 - 2389
14. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler Jr GB (1994) Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 94: 2475-2480, doi:10.1172/JCI117616
15. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96: 1856 - 1865
16. Nissen-Meyer R (1964) Prophylactic endocrine treatment in carcinoma of the breast. Clin Radiol 15: 152- 160
17. O'Malley BW (2005) A life-long search for the molecular pathways of steroid hormone action. Mol Endocrinol 19: 1402 - 1411
18. Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunters A, O'Hare MJ, Warner M, Gustafsson JA, Coombes RC, Lam EW (2004) The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol 33: 35 - 50
19. Paris F, Servant N, Terouanne B, Balaguer P, Nicolas JC, Sultan C (2002) A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children. J Clin Endocrinol Metab 87: 791 - 797
20. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622
21. Roy P, Franks S, Read M, Huhtaniemi IT (2006) Determination ofandrogen bioactivity in human serum samples using a recombinant cell based in vitro bioassay. J Steroid Biochem Mol Biol 101: 68 - 77
22. Sievernich A, Wildt L, Lichtenberg-Frate H (2004) In vitro bioactivity of 17alpha-estradiol. J Steroid Biochem Mol Biol 92: 455-463
23. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 76: 401 - 405
24. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190-197
25. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270- 282
26. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336: 611 - 617